An eczema drug from Nektar Therapeutics maintained skin responses in a one-year study, meeting and in some cases exceeding ...
We discuss financial outlooks from Novo Nordisk and Eli Lilly, a closer look at why manufacturing problems have slowed the ...
With shares down more than 40% since November, the risk-reward for Nektar Therapeutics has shifted ahead of pivotal clinical ...
The Food and Drug Administration has rejected a rare-disease gene therapy from Regenxbio, the company said Monday.
Ocular Therapeutix and Eyepoint Pharmaceuticals are developing competing eye treatments, and the competition appears to be getting heated.
The Corcept Therapeutics drug is relacorilant. A liver-safety risk puts its future — for rare disease and cancer — in doubt.
ImmunityBio Chairman Patrick Soon-Shiong mischaracterized talks with the FDA over the company's cancer drug, sources say.
Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results